The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring  MET  mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses were seen in all patients regardless of how many previous drugs they had been treated...